All In Biotech

Drug Trial Radar · NCT04855045

An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene.

An Open-Label, Dose Escalation and Double-Masked, Randomized, Controlled Study to Evaluate the Safety and Tolerability of Sepofarsen in Pediatric Subjects <8 Years of Age With Leber Congenital Amaurosis Type 10 (LCA10) Due to the c.2991 +1655A>G (p.Cys998X) Mutation.

Last checked: Nov 19, 2026Latest source record: Mar 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

15

Planned (sponsor's estimate)

Start

Mar 23, 2021

Primary completion

Dec 2023

Study completion Dec 2023

Sponsor

Lead sponsor
ProQR TherapeuticsIndustry
Sponsor type
Industry
First posted
Apr 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 0 years, up to 7 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PQ-110-005 (BRIGHTEN) is an open-label, dose escalation and double-masked, randomized, controlled study evaluating safety and tolerability of sepofarsen administered via intravitreal (IVT) injection in pediatric subjects (\<8 years of age) with LCA10 due to the c.2991+1655A\>G mutation over 24 months of treatment.

Conditions

  • Leber Congenital Amaurosis 10
  • Blindness
  • Leber Congenital Amaurosis
  • Vision Disorders
  • Sensation Disorders
  • Neurologic Manifestations
  • Eye Diseases
  • Eye Disorders Congenital
  • Retinal Disease
  • Retinal Degeneration
  • Retinal Dystrophies

Interventions

  • sepofarsenDrug

    RNA antisense oligonucleotide for intravitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of ocular adverse events (AEs)Time frame: 24 months
  2. Incidence and severity of non-ocular adverse events (AEs)Time frame: 24 months

Locations

9 sites in 7 countries. Site status is shown where the registry gives one.

  • Universitair Ziekenhuis Gent (UZ)

    Ghent, Belgium · Recruiting

  • INRET Clinica e Centro de Pesquisa / Santa Casa BH

    Belo Horizonte, Brazil · Recruiting

  • Federal University of Sao Paulo - Hospital Sao Paulo

    São Paulo, Brazil · Recruiting

  • University of Alberta

    Edmonton, Alberta, Canada · Not yet recruiting

  • Justus-Liebig Universität - Department of Ophthalmology

    Giessen, Germany · Recruiting

  • University of Tübingen - Institute for Ophthalmic Research

    Tübingen, Germany · Not yet recruiting

  • Eye Clinic University of Campania Liugi Vanvitelli

    Naples, Italy · Not yet recruiting

  • Amsterdam University Medica Center - Locatie AMC

    Amsterdam, Netherlands · Recruiting

  • Moorfields Eye Hospital - NHS Foundation Trust

    London, United Kingdom · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.